
Researchers zero in on therapeutic target for aggressive uterine cancer
A common mutation in a rare cancer subtype leads researchers to an already-approved drug that shows promise against uterine serous carcinoma.
Staci Vernick is a contributing health and science writer. With expertise in healthcare, medical and science communications and a passion for evocative storytelling, Staci has directed communications for academic medical centers and biomedical research organizations, including Johns Hopkins Children’s, The Wistar Institute and the American Association for Cancer Research. A former journalist, she has written on topics ranging from children’s health to cancer biology to health policy.
A common mutation in a rare cancer subtype leads researchers to an already-approved drug that shows promise against uterine serous carcinoma.
Researchers identify genetic variants that lead to a severe developmental syndrome. The findings could mean better screening and diagnosis for patients with inherited syndromes.
Michigan Medicine researchers identify a potential therapeutic target for neurodegenerative conditions using animal models.
A team led by U-M researchers discovered that a noninvasive imaging biomarker can identify small airway damage in COPD patients.